{"title":"K562-mbIL-18/-21喂料细胞自然杀伤细胞扩增的优化及无喂料细胞产物的保证","authors":"Hantae Jo,Yujung Jo,Seung Kwon Koh,Jinho Kim,SoonHo Kweon,Jeehun Park,Hyun-Young Kim,Duck Cho,Mijeong Lee","doi":"10.3343/alm.2025.0168","DOIUrl":null,"url":null,"abstract":"Background\r\nCancer cell line-derived feeder cells enhance natural killer (NK) cell expansion; however, concerns regarding viable residual feeder cells in the final product limit their use. Evidence supporting the safety of NK-sensitive K562-based feeders, even when irradiated, is scarce. We optimized an NK cell expansion protocol using genetically engineered K562-mbIL-18/-21 (GE-K562) feeder cells and clinical-grade media and confirmed the absence of residual feeder cells.\r\n\r\nMethods\r\nNK cell expansion efficiency was compared between feeder-free and feeder-based systems using CTS NK-Xpander Medium. To achieve optimal NK expansion, various peripheral blood mononuclear cell (PBMC)-to-feeder ratios and re-stimulation frequencies were tested over 21 days. Flow cytometry and BCR::ABL1 quantitative reverse transcription PCR (RT-qPCR) were used to confirm the absence of feeder cells in the final NK cell product.\r\n\r\nResults\r\nFeeder-based systems showed superior NK cell fold expansion compared with that of feeder-free systems. Among feeder-based conditions, NK cells expanded 5,224-fold at a 2:1 PBMC-to-feeder ratio after 3 weeks, relative to 1,450-fold at a 6:1 ratio (P <0.05). Re-stimulation on days 7 and 14 further increased expansion up to 261,457-fold. Irradiated feeder cells showed no proliferation and were eliminated within 3-6 days. On day 21, flow cytometry and BCR::ABL1 RT-qPCR results confirmed the absence of residual feeder cells.\r\n\r\nConclusions\r\nOur optimized NK cell expansion protocol using irradiated GE-K562 feeder cells and clinical-grade media offers a safe and scalable approach to generating large numbers of NK cells, supporting its potential use in clinical immunotherapy applications.","PeriodicalId":8421,"journal":{"name":"Annals of Laboratory Medicine","volume":"32 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimization of Natural Killer Cell Expansion with K562-mbIL-18/-21 Feeder Cells and Assurance of Feeder Cell-free Products.\",\"authors\":\"Hantae Jo,Yujung Jo,Seung Kwon Koh,Jinho Kim,SoonHo Kweon,Jeehun Park,Hyun-Young Kim,Duck Cho,Mijeong Lee\",\"doi\":\"10.3343/alm.2025.0168\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background\\r\\nCancer cell line-derived feeder cells enhance natural killer (NK) cell expansion; however, concerns regarding viable residual feeder cells in the final product limit their use. Evidence supporting the safety of NK-sensitive K562-based feeders, even when irradiated, is scarce. We optimized an NK cell expansion protocol using genetically engineered K562-mbIL-18/-21 (GE-K562) feeder cells and clinical-grade media and confirmed the absence of residual feeder cells.\\r\\n\\r\\nMethods\\r\\nNK cell expansion efficiency was compared between feeder-free and feeder-based systems using CTS NK-Xpander Medium. To achieve optimal NK expansion, various peripheral blood mononuclear cell (PBMC)-to-feeder ratios and re-stimulation frequencies were tested over 21 days. Flow cytometry and BCR::ABL1 quantitative reverse transcription PCR (RT-qPCR) were used to confirm the absence of feeder cells in the final NK cell product.\\r\\n\\r\\nResults\\r\\nFeeder-based systems showed superior NK cell fold expansion compared with that of feeder-free systems. Among feeder-based conditions, NK cells expanded 5,224-fold at a 2:1 PBMC-to-feeder ratio after 3 weeks, relative to 1,450-fold at a 6:1 ratio (P <0.05). Re-stimulation on days 7 and 14 further increased expansion up to 261,457-fold. Irradiated feeder cells showed no proliferation and were eliminated within 3-6 days. On day 21, flow cytometry and BCR::ABL1 RT-qPCR results confirmed the absence of residual feeder cells.\\r\\n\\r\\nConclusions\\r\\nOur optimized NK cell expansion protocol using irradiated GE-K562 feeder cells and clinical-grade media offers a safe and scalable approach to generating large numbers of NK cells, supporting its potential use in clinical immunotherapy applications.\",\"PeriodicalId\":8421,\"journal\":{\"name\":\"Annals of Laboratory Medicine\",\"volume\":\"32 1\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Laboratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3343/alm.2025.0168\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Laboratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3343/alm.2025.0168","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
肿瘤细胞系来源的饲养细胞增强自然杀伤细胞(NK)的扩增;然而,对最终产品中残留的饲养细胞的担忧限制了它们的使用。支持对nk敏感的基于k562的喂食器的安全性的证据,即使经过辐照,也很少。我们使用基因工程K562-mbIL-18/-21 (GE-K562)饲养细胞和临床级培养基优化了NK细胞扩增方案,并证实没有残留的饲养细胞。方法采用CTS nk - expander培养基,比较无投料系统和有投料系统的snk细胞扩增效率。为了达到最佳NK扩增,在21天内测试了不同的外周血单核细胞(PBMC)与饲料的比例和再刺激频率。用流式细胞术和BCR::ABL1定量反转录PCR (RT-qPCR)证实最终NK细胞产物中不存在饲养细胞。结果加料系统的NK细胞折叠扩增率高于无加料系统。在以饲料为基础的条件下,在2:1的pbmc与饲料比例下,NK细胞在3周后扩增5,224倍,而在6:1的比例下扩增1,450倍(P <0.05)。第7天和第14天的再次刺激进一步增加了膨胀,达到261,457倍。辐照后的饲养细胞无增殖,3-6天内消失。第21天,流式细胞术和BCR::ABL1 RT-qPCR结果证实没有残留的饲养细胞。结论采用辐照的GE-K562饲养细胞和临床级培养基进行NK细胞扩增,是一种安全、可扩展的大量NK细胞扩增方法,支持其在临床免疫治疗中的潜在应用。
Optimization of Natural Killer Cell Expansion with K562-mbIL-18/-21 Feeder Cells and Assurance of Feeder Cell-free Products.
Background
Cancer cell line-derived feeder cells enhance natural killer (NK) cell expansion; however, concerns regarding viable residual feeder cells in the final product limit their use. Evidence supporting the safety of NK-sensitive K562-based feeders, even when irradiated, is scarce. We optimized an NK cell expansion protocol using genetically engineered K562-mbIL-18/-21 (GE-K562) feeder cells and clinical-grade media and confirmed the absence of residual feeder cells.
Methods
NK cell expansion efficiency was compared between feeder-free and feeder-based systems using CTS NK-Xpander Medium. To achieve optimal NK expansion, various peripheral blood mononuclear cell (PBMC)-to-feeder ratios and re-stimulation frequencies were tested over 21 days. Flow cytometry and BCR::ABL1 quantitative reverse transcription PCR (RT-qPCR) were used to confirm the absence of feeder cells in the final NK cell product.
Results
Feeder-based systems showed superior NK cell fold expansion compared with that of feeder-free systems. Among feeder-based conditions, NK cells expanded 5,224-fold at a 2:1 PBMC-to-feeder ratio after 3 weeks, relative to 1,450-fold at a 6:1 ratio (P <0.05). Re-stimulation on days 7 and 14 further increased expansion up to 261,457-fold. Irradiated feeder cells showed no proliferation and were eliminated within 3-6 days. On day 21, flow cytometry and BCR::ABL1 RT-qPCR results confirmed the absence of residual feeder cells.
Conclusions
Our optimized NK cell expansion protocol using irradiated GE-K562 feeder cells and clinical-grade media offers a safe and scalable approach to generating large numbers of NK cells, supporting its potential use in clinical immunotherapy applications.
期刊介绍:
Annals of Laboratory Medicine is the official journal of Korean Society for Laboratory Medicine. The journal title has been recently changed from the Korean Journal of Laboratory Medicine (ISSN, 1598-6535) from the January issue of 2012. The JCR 2017 Impact factor of Ann Lab Med was 1.916.